Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 6, 2017, Pages 901-905

  von Scholten, Bernt Johan ^a   Persson, Frederik ^a   Rosenlund, Signe ^a   Eugen Olsen, Jesper ^b   Pielak, Tomasz ^c   Faber, Jens ^d   Hansen, Tine W ^a   Rossing, Peter ^a,e,f  

^a STENO DIABETES CENTER   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c ITTI Sp Z Oo   (Poland)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

clinical trial; GLP 1 analogue; liraglutide

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; COPEPTIN; CREATININE; LIRAGLUTIDE; PLACEBO; PROADRENOMEDULLIN; TUMOR NECROSIS FACTOR; UROKINASE RECEPTOR; ADRENOMEDULLIN; ANTIDIABETIC AGENT; GLYCOPEPTIDE; MID-REGIONAL PRO-ADRENOMEDULLIN, HUMAN; MIDREGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE, HUMAN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; RISK FACTOR;

ADRENOMEDULLIN; AGED; ALBUMINURIA; ATRIAL NATRIURETIC FACTOR; BIOMARKERS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYCOPEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85019886909     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12884     Document Type: Article

References (17)

1. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106-2111.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874.
3. Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: individual effects of treatment. J Diabetes Complications. 2017;31(1):162-168.
4. von Scholten BJ, Persson F, Rosenlund S, et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes Metab. 2017;19:239-247.
5. van Genugten RE, Moller-Goede DL, van Raalte DH, Diamant M. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab. 2013;15(7):593-606.
6. von Scholten BJ, Reinhard H, Hansen TW, et al. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. J Diabetes Complications. 2016;30(2):248-255.
7. Theilade S, Lyngbaek S, Hansen TW, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med. 2015;277(3):362-371.
8. Landman GW, van Dijk PR, Drion I, et al. Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30). Diabetes Care. 2014;37(3):839-845.
9. van Hateren KJ, Landman GW, Kleefstra N, et al. The midregional fragment of pro-A-type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (ZODIAC-25). Diabetes Care. 2013;36(5):1347-1352.
10. Riphagen IJ, Boertien WE, Alkhalaf A, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care. 2013;36(10):3201-3207.
11. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
12. Mita T, Watada H. Glucagon like peptide-1 and atherosclerosis. Cardiovasc Hematol Agents Med Chem. 2012;10(4):309-318.
13. Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014;13:49.
14. von Scholten BJ, Reinhard H, Hansen TW, et al. Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:59.
15. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567-575.
16. von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med. 2015;32(3):343-352.
17. von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications. 2015;29(5):670-674.